AusperBio
AusperBio Raises $120M Series C for Hepatitis B Oligonucleotide Therapies
AusperBio announced $120M in Series C financing on August 27, 2026. AusperBio closed a $120 million Series C led by a strategic investor, with new investor RA Capital participating, to advance its hepatitis B candidate AHB-137.
Round details
The financing includes backing from RA Capital Management, HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, CDH Investments. The company did not publish a valuation with the announcement.
- Round: Series C
- Capital announced: $120M
- Total funding reported: $360M
How the company plans to use the capital
AusperBio said the financing will support continued development of AHB-137, including its Phase 3 registrational program and commercialization readiness. Proceeds will also accelerate AHB-171, advance next-generation combination approaches for chronic hepatitis B, and further expand the company’s pipeline.
Why this matters for GTM teams
AusperBio describes itself as a near-commercial company with an initial focus on achieving a functional cure for chronic hepatitis B, and said existing investors continued their support in the round.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: AusperBio Series C announcement.
Company Info
Investors (7)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started